Combination of BRAF and VEGF Inhibitors
AssigneeGlaxoSmithKline LLC
InventorRakesh Kumar
Life of this patent
Estimating the term…
Abstract
A novel combination comprising the VEGFR inhibitor 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, with a B-Raf inhibitor, particularly N-(3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl)-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of VEGFR and/or B-Raf is beneficial.
Claims10
A combination comprising:
- (i) a compound of formula (I)
- or a pharmaceutically acceptable salt thereof;
- and
- (ii) a compound of formula (H)
- or a pharmaceutically acceptable salt thereof.
(canceled)
A method of treating a susceptible cancer in a human in need thereof which comprises the administration of therapeutically effective amounts of
- (i) a compound of formula (I)
- or a pharmaceutically acceptable salt thereof
- and
- (ii) a compound of formula (II)
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.